This Study Will Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of MET097 in Adult Participants With Overweight or Obesity

Inclusion Criteria: * Overweight/Obese but otherwise healthy adult male or female with a BMI within 27.0 kg/m2 to 38.0 kg/m2, inclusively * At least 18 years of age but not older than 70 years of age * Have no clinically significant diseases captured in the medical history or evidence of clinically significant findings on the physical examination (including vital signs) and/or ECG, as determined by an Investigator * Estimated glomerular filtration rate (eGFR) ≥90 mL/min at the Screening visit Exclusion Criteria: * Female who is lactating or who is pregnant according to the pregnancy test at the Screening visit or prior to the first study drug administration * Seated blood pressure higher than 160/95 mmHg at the Screening visit * Elevated resting pulse greater than 100 beats per minute at Screening visit * Presence of clinically significant ECG abnormalities * Diagnosis of diabetes (type 1 or type 2) * Participation in a weight loss program with or without pharmacotherapy during the 3 months prior to study administration * Obesity induced by endocrinologic disorders (e.g., Cushing's syndrome) or diagnosed monogenetic or syndromic forms of obesity (e.g., Melanocortin 4 Receptor deficiency or Prader-Willi Syndrome). * Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type